The Ministry of Food and Drug Safety (MFDS) said on Thursday it approved UCB Korea's myasthenia gravis treatment, Zilbrysq Prefilled Syringe Injection (zilucoplan sodium).

Generalized myasthenia gravis is an antibody-mediated autoimmune disease characterized by chronic systemic or localized muscle weakness caused by autoantibodies that disrupt the neuromuscular junction.

Zilbrysq inhibits complement-mediated neuromuscular junction damage caused by anti-acetylcholine receptor autoantibodies and is therapeutically effective.

It is approved for use as an adjunct to standard therapy for the treatment of anti-acetylcholine receptor antibody-positive systemic myasthenia gravis in adults.

“This approval will expand the treatment options for adult patients with myasthenia gravis,” the MFDS said. “Zilbrysq can be self-administered by subcutaneous injection, providing convenience for patients.”